Preview

Российский кардиологический журнал

Расширенный поиск

ДЛИТЕЛЬНАЯ ТЕРАПИЯ ВАРФАРИНОМ У БОЛЬНЫХ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ БЕЗ ПОРАЖЕНИЯ КЛАПАНОВ СЕРДЦА С ЦЕЛЬЮ ПРОФИЛАКТИКИ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ

https://doi.org/10.15829/1560-4071-2005-6-50-56

Полный текст:

Об авторах

Г. В. Аркадьева
Московский государственный медико-стоматологический университет, 52 КДЦ Минобороны России
Россия


А. Э. Радзевич
Московский государственный медико-стоматологический университет, 52 КДЦ Минобороны России
Россия


Список литературы

1. Панченко Е.П. Профилактика кардиоэмболического инсульта у больных мерцательной аритмии//Кардиоваскулярная терапия и профилактика. -2003. -№2(3). -С. 64-69.

2. Atrial fibrillation investigators. Risk Factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooleddata from five randomized controlled trials//Arch Intern Med 1994; 154: 1449-1457.ъ

3. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation//Eur Heart J 2001;22:1852-1923.

4. FAFT (European Atrial Fibrillation) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke//Lancet 1993; 342: 1255-1262.

5. Film S.D., McDommel M., Matin D. et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Groop//Ann Intern. Med. 1993;118:511-520.

6. Green C.J., Hadorn D.C., Bassett K. et al. Anticoagulation in chronic nonvalvular atrial fibrillation: A critical appraisal and meta-analysis//Can. J. Cardiol. 1997; v.13: 811-815.

7. Gorter J.W. Major bleeding during anticoagulation after cerebral ischemia: patters and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT)//Neurology 1999;53: 1319-1327.

8. Hart R.G., Halperin J.L., Pearce L.A., et al. Lessons from the stroke prevention in atrial fibrillation trials//Ann Intern Med 2003; v.138 (10): 831-838

9. Halperin J.L. Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)//Am. Heart J. 2003Sep;146(3): 431-438.

10. Hart R.G., Pearce L.A., McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials//The Stroke Prevention in Atrial Fibrillation (SPAF) Invetigators. 1999;30: 1223-1229.

11. Lidell С., Svedberg L.E., Lindell Р., Bandh S., Job В., Wallentin L. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation//Thromb Haemost. 2003 May; 89(5): 842-846.

12. Mant J.W., Richards S.H., Hobbs F.D. et al.; Midlands Research Consortium of General Practice. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA):a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]//BMC Cardiovasc Disord.2003 Aug 26;3(1):9.

13. Muller I,. Massberg S., Zierhut W. et al. Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB)//Pathophysiol Haemost Thromb. 2002 Jan-Feb;32(l):16-24.

14. Nagpal S., Anderson D., Putnam W. et al. Stroke prevention in hospitalized patients with atrial fibrillation: a population-based study//Can J Clin Pharmacol. 2003 Winter;10(4): 197-201.

15. Pengo V., Legnani C., Noventa E. et al. ISCOAT Study Group (Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study//Thromb Haemost 2001;85:418-422.

16. Risk stratification and anticoagulation in non-valvular atrial fibrillation. Adapted from Lip et al.//BMJ 2002; 325: 1022-1025.

17. Roldan V., Marin E., Marco P. et al. Anticoagulant therapy modifies fibrinolytic dysfunction in chronic atrial fibrillation//Haemostasis 2000; 30(4): 219-224.

18. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation randomised clinical trial//Lancet. 1996; v.348: 633-638.

19. Stoddard M.F., Singh P., Dawn B. et al. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrilfation//Am Heart J. 2003;145:4:1112-1118.

20. Thamilarasan M., Klin A.L. Transesophageal Echocardiography (TEE) in Atrial Fibrfflation//Cardial clin 2000;18:4:1-18.


Для цитирования:


Аркадьева Г.В., Радзевич А.Э. ДЛИТЕЛЬНАЯ ТЕРАПИЯ ВАРФАРИНОМ У БОЛЬНЫХ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ БЕЗ ПОРАЖЕНИЯ КЛАПАНОВ СЕРДЦА С ЦЕЛЬЮ ПРОФИЛАКТИКИ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ. Российский кардиологический журнал. 2005;(6):50-56. https://doi.org/10.15829/1560-4071-2005-6-50-56

For citation:


Arkadyeva G.V., Radzevich A.E. Long-term warfarin therapy in thromboembolism prevention among atrial fibrillation patients without heart valve pathology. Russian Journal of Cardiology. 2005;(6):50-56. (In Russ.) https://doi.org/10.15829/1560-4071-2005-6-50-56

Просмотров: 41


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)